A Phase 2 Study of Duvelisib Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated with a Brutons Tyrosine Kinase Inhibitor (BTKi)
Sponsor: |
Verastem, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR6847 |
U.S. Govt. ID: |
NCT03370185 |
Contact: |
Nicole Lamanna, MD: 646-317-5205 / nl2129@cumc.columbia.edu |
The main goal of this study is to find out about how duvelisib acts in patients with CLL/SLL who were previously treated with a BTKi (Bruton Tyrosine Kinase inhibitor - commercially available ibrutinib or another investigational BTKi). Duvelisib is an investigational drug, meaning that it is not FDA approved, designed to try to stop cancer growth by blocking PI3 kinase activity. PI3 kinase is an enzyme in the body that is overproduced by some cancers, can fuel cancer growth and is known to be increased in many blood cancers.
This study is closed
Investigator
Nicole Lamanna, MD
Are you at least 18 years of age? |
Yes |
No |
Do you have a diagnosis of CLL or SLL? |
Yes |
No |
Have you received at least one prior therapy for CLL or SLL? |
Yes |
No |
Was your prior therapy BTKi therapy? |
Yes |
No |